Skip to content

US · HYFT · BIOTECHNOLOGY

MindWalk Holdings Corp. (HYFT) intrinsic value and stock valuation

$0.68as of 2026-11-21 · Mkt cap 62.02M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MindWalk Holdings Corp. DCF and intrinsic value

InvestorsCraft values HYFT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HYFT’s statements →

MindWalk Holdings Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Austin, TX 78701 mindwalkai.com

How the business is doing

Fiscal 2011–2026, USD

Revenue
$15.3M-3.1% 5y CAGRd
20112026
Net income
-$-13.74M
20112026
Free cash flow
-$-12.66M
20112026
Total equity
$11.7M-27.1% 5y CAGRd
20112026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2026, USD
20262025202420232022
Revenue$15.3M$24.5M$24.5M$20.7M$19.4M
Operating income-$-14.71M-$-12.2M-$-13.76M-$-25.61M-$-16.67M
Net income-$-13.74M-$-30.23M-$-26.11M-$-26.56M-$-16.71M
EPSd-$-296.25K-$-905.63K-$-1.02M-$-1.07M-$-848.65K
Operating cash flow-$-12.27M-$-6.41M-$-4.25M-$-19.83M-$-9.92M
Capital expenditure-$-390K-$-800K-$-1.4M-$-1.5M-$-1.26M
Free cash flow-$-12.66M-$-7.21M-$-5.64M-$-21.33M-$-11.18M
Total assets$21.3M$44.4M$60M$77.8M$93.5M
Total debt$3.52M$13.4M$13.7M$14.3M$2.77M
Net debt-$-7.81M$2.74M$10.2M$5.99M-$-27.2M
Total equity$11.7M$23.6M$33.9M$57.8M$75.3M
Cash and short-term investments$11.3M$10.7M$3.46M$8.28M$30M
Income statement
20262025202420232022
Revenue$15.3M$24.5M$24.5M$20.7M$19.4M
Cost of revenue$6.31M$11M$12.5M$9.1M$8.38M
Gross profit$9.01M$13.6M$12.1M$11.6M$11M
Research and development expenses$4.86M$4.94M$4.04M$14.1M$7.66M
Selling, general and administrative expenses$18.9M$19M$19.1M$19M$18.1M
Other expenses$0.00$1.77M$2.64M$4.08M$1.94M
Operating expenses$23.7M$25.7M$25.8M$37.2M$27.7M
Cost and expenses$30M$36.7M$38.3M$46.3M$36M
Interest income$0.00$0.00$20K$120K$280K
Interest expense$0.00$10K$20K$30K$90K
Depreciation and amortization$1.58M$5.12M$5.74M$6.68M$3.77M
Ebitda-$-13.13M-$-28.86M-$-22.95M-$-21.04M-$-11.99M
Operating income-$-14.71M-$-12.2M-$-13.76M-$-25.61M-$-16.67M
Total other income/expenses, net-$-610K-$-22.07M-$-14.94M-$-2.14M$820K
Income before tax-$-15.31M-$-34.27M-$-28.7M-$-27.75M-$-15.85M
Income tax expense-$-440K-$-4.03M-$-2.59M-$-1.19M$860K
Net income-$-13.74M-$-30.23M-$-26.11M-$-26.56M-$-16.71M
Weighted average shares outstanding$46.4M$33.4M$25.6M$24.9M$19.7M
Weighted average diluted shares outstanding$46.4M$33.4M$25.6M$24.9M$19.7M
Balance sheet
20262025202420232022
Cash and short-term investments$11.3M$10.7M$3.46M$8.28M$30M
Net receivables$3.58M$4.81M$4.07M$3.88M$3.41M
Inventory$490K$2.1M$2.14M$2.06M$1.61M
Total current assets$16.2M$18.8M$11.5M$16.8M$37.5M
Property, plant and equipment, net$4.07M$16.3M$16.7M$10.7M$3.71M
Goodwill and intangible assets$0.00$9.3M$31.2M$50.1M$52.1M
Long-term investments$130K$90K$60K$120K$140K
Total non-current assets$5.15M$25.7M$48.5M$61M$56M
Total assets$21.3M$44.4M$60M$77.8M$93.5M
Accounts payable$4.17M$5.28M$4.07M$2.48M$4.77M
Short-term debt$460K$1.85M$1.56M$1.94M$2.3M
Deferred revenue$1.07M$1.09M$0.00$720K$1.03M
Total current liabilities$5.78M$9.01M$8.12M$5.92M$9.29M
Long-term debt$3.06M$11.6M$12.1M$12.3M$470K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3.83M$11.8M$17.9M$14.1M$9.07M
Capital lease obligations$3.06M$13.4M$13.7M$7.27M$1.46M
Total liabilities$9.61M$20.8M$26.1M$20M$18.4M
Common stock$137M$136.4M$119.8M$117.5M$114.6M
Retained earnings-$-142.5M-$-128.79M-$-100.27M-$-73.09M-$-46.53M
Accumulated other comprehensive income (loss)$3.12M$3.22M$2.02M$2.62M-$-2.48M
Total equity$11.7M$23.6M$33.9M$57.8M$75.3M
Total investments$130K$90K$60K$120K$140K
Total debt$3.52M$13.4M$13.7M$14.3M$2.77M
Net debt-$-7.81M$2.74M$10.2M$5.99M-$-27.2M
Cash flow statement
20262025202420232022
Net income-$-14.87M-$-30.23M-$-27.18M-$-26.56M-$-16.71M
Depreciation and amortization$1.58M$5.12M$5.74M$6.68M$3.77M
Stock-based compensation$0.00$450K$1.53M$1.94M$3.08M
Change in working capital-$-2.03M$280K$2.4M-$-3.28M$580K
Accounts receivable-$-2.25M-$-390K-$-240K-$-560K$160K
Inventory-$-50K$100K-$-100K-$-180K-$-500K
Accounts payable-$-210K$590K$990K-$-1.55M$780K
Net cash provided by operating activities-$-12.27M-$-6.41M-$-4.25M-$-19.83M-$-9.92M
Investments in property, plant and equipment-$-390K-$-800K-$-1.4M-$-1.5M-$-1.26M
Acquisitions, net$14M$0.00-$-150K-$-590K-$-3.69M
Net cash used for investing activities$13.3M-$-800K-$-1.56M-$-1.97M-$-5.21M
Common stock issued$880K$12.2M$1.75M$720K$3.85M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$110K$14.9M$1.02M-$-620K$2.88M
Net change in cash$840K$7.25M-$-4.82M-$-21.68M-$-11.79M
Cash at end of period$11.3M$10.8M$3.54M$8.37M$30.1M
Operating cash flow-$-12.27M-$-6.41M-$-4.25M-$-19.83M-$-9.92M
Capital expenditure-$-390K-$-800K-$-1.4M-$-1.5M-$-1.26M
Free cash flow-$-12.66M-$-7.21M-$-5.64M-$-21.33M-$-11.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MindWalk Holdings Corp.

        MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.

        CEO
        Jennifer Lynne Bath
        Employees
        102
        Beta
        0.83

        Explore

        Frequently asked questions

        What is the intrinsic value of MindWalk Holdings Corp. (HYFT)?

        InvestorsCraft does not currently publish an intrinsic value for HYFT. How the IC value is calculated.

        Is HYFT undervalued?

        InvestorsCraft does not publish an undervaluation signal for HYFT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.